Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES014 Administered in Patients Locally Advanced or Metastatic Solid Tumours

NCT05717348 is registered in ClinicalTrials.gov with Elpiscience (Suzhou) Biopharma, Ltd. as lead sponsor.

NCT NCT05717348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05717348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES014 Administered in Patients Locally Advanced or Metastatic Solid Tumours
Lead sponsor
Elpiscience (Suzhou) Biopharma, Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 24, 2023
Completion date
February 28, 2027
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced solid tumor, metastatic solid tumor, solid tumor